Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205-Reference-Cited by-同舟云学术

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

Published:2014-04-16 Issue:232 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Dhodapkar Madhav V.¹,Sznol Mario¹,Zhao Biwei²,Wang Ding³,Carvajal Richard D.⁴,Keohan Mary L.⁴,Chuang Ellen⁵,Sanborn Rachel E.⁶,Lutzky Jose⁷,Powderly John⁸,Kluger Harriet¹,Tejwani Sheela³,Green Jennifer²,Ramakrishna Venky²,Crocker Andrea²,Vitale Laura²,Yellin Michael²,Davis Thomas²,Keler Tibor²

Affiliation:

1. Yale Cancer Center, New Haven, CT 06520, USA.

2. Celldex Therapeutics Inc., Hampton, NJ 08827, USA.

3. Henry Ford Health Systems, Detroit, MI 48202, USA.

4. Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

5. Weill Cornell Medical College, New York, NY 10065, USA.

6. Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR 97213, USA.

7. Mount Sinai Medical Center, Miami Beach, FL 33140, USA.

8. Carolina BioOncology Institute, Huntersville, NC 28078, USA.

Abstract

Dendritic cell targeting safely leads to integrated humoral and cellular immunity when combined with TLR agonists in cancer patients.

Publisher